# A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer

Source: https://onco.cc/trials/nct06114511/  
OnCo record `nct06114511` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Trastuzumab brengitecan in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.

## Summary

A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer is a phase 1/2 interventional study registered as NCT06114511 by Sichuan Baili Pharmaceutical Co., Ltd., with 78 participants enrolled, started 2024-04-24 and due to reach its primary completion in 2026-12. Interventions recorded: BL-M07D1. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06114511
- Phase: 1/2
- Setting: A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 for Injection in Patients With HER2 Mutated, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 78

## Sources

- ClinicalTrials.gov NCT06114511: https://clinicaltrials.gov/study/NCT06114511

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Trastuzumab brengitecan](https://onco.cc/drugs/trastuzumab-brengitecan/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct06114511.json